Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant.
We determined gut mucosal barrier injury (MBI) among 129 recipients of an allogeneic or autologous haematopoietic stem cell transplant (HSCT) who had been given different myeloablative regimens by measuring integrity using the lactulose/rhamnose (RHA) ratio and absorption using the ratios of rhamnose/3-O-methylglucose and xylose/3-O-methylglucose. Regimens that did not contain idarubicin induced oral mucositis and disturbed gut integrity and absorption earlier than did those containing the anthracycline. By contrast, regimens containing idarubicin induced more severe and prolonged oral and gut MBI. Gut integrity and absorption of most patients were still abnormal at discharge from hospital. These results confirm that the integrity and absorptive capacity of the gut is affected adversely by myeloablative regimens in general, although only two patterns of mucosal injury emerged depending on whether or not idarubicin was used.
Blijlevens
N M A
NM
Department of Haematology, University Medical Centre, St Radboud, Nijmegen, The Netherlands. n.blijlevens@hemat.umcn.nl
Donnelly
J P
JP
de Pauw
B E
BE
D000328:Adult; D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D015255:Idarubicin / Q000009:adverse effects; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007792:Lactulose / Q000378:metabolism / Q000652:urine; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects*; D010539:Permeability / Q000187:drug effects; D011446:Prospective Studies; D012210:Rhamnose / Q000378:metabolism / Q000652:urine; D013280:Stomatitis / Q000139:chemically induced; D019172:Transplantation Conditioning / Q000009:adverse effects*
D018943:Anthracyclines; D000970:Antineoplastic Agents; D019653:Myeloablative Agonists; D007792:Lactulose; D012210:Rhamnose; D015255:Idarubicin